Maryland | 001-08895 | 33-0091377 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Common Stock, $1.00 par value | DOC | New York Stock Exchange |
No. | Description | |||||||
99.1 | ||||||||
99.2 | ||||||||
99.3 | ||||||||
104 | Cover Page Interactive Data File (embedded within the inline XBRL document and contained in Exhibit 101). |
Date: July 25, 2024 | ||||||||
Healthpeak Properties, Inc. | ||||||||
By: | /s/ Peter A. Scott | |||||||
Peter A. Scott | ||||||||
Chief Financial Officer |
Three Months Ended June 30, 2024 |
Three Months Ended June 30, 2023 |
||||||||||||||||||||||
(in thousands, except per share amounts) | Amount | Per Share | Amount | Per Share | |||||||||||||||||||
Net income, diluted | $ | 145,904 | $ | 0.21 | $ | 51,750 | $ | 0.09 | |||||||||||||||
Nareit FFO, diluted | 318,610 | 0.44 | 247,754 | 0.45 | |||||||||||||||||||
FFO as Adjusted, diluted | 320,220 | 0.45 | 251,540 | 0.45 | |||||||||||||||||||
AFFO, diluted | 276,947 | 0.39 | 223,197 | 0.40 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
||||||||||||||||||||||
(in thousands, except per share amounts) | Amount | Per Share | Amount | Per Share | |||||||||||||||||||
Net income, diluted | $ | 152,345 | $ | 0.23 | $ | 169,449 | $ | 0.31 | |||||||||||||||
Nareit FFO, diluted | 479,906 | 0.72 | 478,200 | 0.86 | |||||||||||||||||||
FFO as Adjusted, diluted | 597,879 | 0.90 | 483,421 | 0.87 | |||||||||||||||||||
AFFO, diluted | 524,599 | 0.79 | 433,195 | 0.78 |
Year-Over-Year Total Merger-Combined SS Cash (Adjusted) NOI Growth | |||||||||||||||||
Three Month | Year-To-Date | ||||||||||||||||
SS Growth % | % of SS | SS Growth % | % of SS | ||||||||||||||
Outpatient Medical | 3.1 | % | 56.1 | % | 2.7 | % | 56.2 | % | |||||||||
Lab | 3.0 | % | 34.4 | % | 2.9 | % | 34.3 | % | |||||||||
CCRC | 20.5 | % | 9.5 | % | 23.4 | % | 9.5 | % | |||||||||
Total Merger-Combined SS Cash (Adjusted) NOI | 4.5 | % | 100.0 | % | 4.4 | % | 100.0 | % |
Disposition Portfolios and Remaining Healthpeak Outpatient Medical Portfolio Summary | ||||||||
Outpatient Medical Portfolios(1) |
||||||||
Dispositions | Remaining Healthpeak | |||||||
Number of properties | 72 | 507 | ||||||
Total square feet | 3.3 million | 36 million | ||||||
Average building size (square feet) | 45,000 | 72,000 | ||||||
Average building age(2) |
28 years | 23 years | ||||||
Percent on-campus or affiliated | 88 | % | 96 | % | ||||
Percent leased to health systems | 57 | % | 68 | % | ||||
Population density(3) |
2,300 | 3,600 | ||||||
Population growth(3) |
2.4 | % | 3.3 | % |
June 30, 2024 |
December 31, 2023 |
||||||||||
Assets | |||||||||||
Real estate: | |||||||||||
Buildings and improvements | $ | 16,448,690 | $ | 13,329,464 | |||||||
Development costs and construction in progress | 739,318 | 643,217 | |||||||||
Land and improvements | 3,005,974 | 2,647,633 | |||||||||
Accumulated depreciation and amortization | (3,796,108) | (3,591,951) | |||||||||
Net real estate | 16,397,874 | 13,028,363 | |||||||||
Loans receivable, net of reserves of $9,143 and $2,830 | 275,478 | 218,450 | |||||||||
Investments in and advances to unconsolidated joint ventures | 927,204 | 782,853 | |||||||||
Accounts receivable, net of allowance of $2,751 and $2,282 | 59,658 | 55,820 | |||||||||
Cash and cash equivalents | 106,886 | 117,635 | |||||||||
Restricted cash | 52,409 | 51,388 | |||||||||
Intangible assets, net | 1,076,087 | 314,156 | |||||||||
Assets held for sale, net | — | 117,986 | |||||||||
Right-of-use asset, net | 440,558 | 240,155 | |||||||||
Other assets, net | 843,554 | 772,044 | |||||||||
Total assets | $ | 20,179,708 | $ | 15,698,850 | |||||||
Liabilities and Equity | |||||||||||
Bank line of credit and commercial paper | $ | 25,000 | $ | 720,000 | |||||||
Term loans | 1,645,456 | 496,824 | |||||||||
Senior unsecured notes | 6,551,155 | 5,403,378 | |||||||||
Mortgage debt | 381,416 | 256,097 | |||||||||
Intangible liabilities, net | 227,370 | 127,380 | |||||||||
Liabilities related to assets held for sale, net | — | 729 | |||||||||
Lease liability | 313,469 | 206,743 | |||||||||
Accounts payable, accrued liabilities, and other liabilities | 709,219 | 657,196 | |||||||||
Deferred revenue | 907,852 | 905,633 | |||||||||
Total liabilities | 10,760,937 | 8,773,980 | |||||||||
Commitments and contingencies | |||||||||||
Redeemable noncontrolling interests | 1,433 | 48,828 | |||||||||
Common stock, $1.00 par value: 1,500,000,000 and 750,000,000 shares authorized; 700,316,807 and 547,156,311 shares issued and outstanding | 700,317 | 547,156 | |||||||||
Additional paid-in capital | 12,859,567 | 10,405,780 | |||||||||
Cumulative dividends in excess of earnings | (4,844,683) | (4,621,861) | |||||||||
Accumulated other comprehensive income (loss) | 42,297 | 19,371 | |||||||||
Total stockholders’ equity | 8,757,498 | 6,350,446 | |||||||||
Joint venture partners | 324,681 | 310,998 | |||||||||
Non-managing member unitholders | 335,159 | 214,598 | |||||||||
Total noncontrolling interests | 659,840 | 525,596 | |||||||||
Total equity | 9,417,338 | 6,876,042 | |||||||||
Total liabilities and equity | $ | 20,179,708 | $ | 15,698,850 |
Three Months Ended June 30, |
Six Months Ended June 30, |
||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||||
Rental and related revenues | $ | 546,781 | $ | 409,967 | $ | 1,008,814 | $ | 802,398 | |||||||||||||||
Resident fees and services | 140,891 | 130,184 | 279,667 | 257,268 | |||||||||||||||||||
Interest income and other | 7,832 | 5,279 | 13,583 | 11,442 | |||||||||||||||||||
Total revenues | 695,504 | 545,430 | 1,302,064 | 1,071,108 | |||||||||||||||||||
Costs and expenses: | |||||||||||||||||||||||
Interest expense | 74,910 | 49,074 | 135,817 | 97,037 | |||||||||||||||||||
Depreciation and amortization | 283,498 | 197,573 | 502,717 | 376,798 | |||||||||||||||||||
Operating | 273,827 | 221,837 | 517,556 | 444,925 | |||||||||||||||||||
General and administrative | 26,718 | 25,936 | 50,017 | 50,483 | |||||||||||||||||||
Transaction and merger-related costs | 7,759 | 637 | 114,979 | 3,062 | |||||||||||||||||||
Impairments and loan loss reserves (recoveries), net | (553) | 2,607 | 10,905 | 394 | |||||||||||||||||||
Total costs and expenses | 666,159 | 497,664 | 1,331,991 | 972,699 | |||||||||||||||||||
Other income (expense): | |||||||||||||||||||||||
Gain (loss) on sales of real estate, net | 122,044 | 4,885 | 125,299 | 86,463 | |||||||||||||||||||
Other income (expense), net | 4,004 | 1,955 | 82,520 | 2,727 | |||||||||||||||||||
Total other income (expense), net | 126,048 | 6,840 | 207,819 | 89,190 | |||||||||||||||||||
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures | 155,393 | 54,606 | 177,892 | 187,599 | |||||||||||||||||||
Income tax benefit (expense) | (2,728) | (1,136) | (16,426) | (1,438) | |||||||||||||||||||
Equity income (loss) from unconsolidated joint ventures | 51 | 2,729 | 2,427 | 4,545 | |||||||||||||||||||
Net income (loss) | 152,716 | 56,199 | 163,893 | 190,706 | |||||||||||||||||||
Noncontrolling interests’ share in earnings | (6,669) | (4,300) | (11,170) | (19,855) | |||||||||||||||||||
Net income (loss) attributable to Healthpeak Properties, Inc. | 146,047 | 51,899 | 152,723 | 170,851 | |||||||||||||||||||
Participating securities’ share in earnings | (214) | (149) | (414) | (1,402) | |||||||||||||||||||
Net income (loss) applicable to common shares | $ | 145,833 | $ | 51,750 | $ | 152,309 | $ | 169,449 | |||||||||||||||
Earnings (loss) per common share: | |||||||||||||||||||||||
Basic | $ | 0.21 | $ | 0.09 | $ | 0.23 | $ | 0.31 | |||||||||||||||
Diluted | $ | 0.21 | $ | 0.09 | $ | 0.23 | $ | 0.31 | |||||||||||||||
Weighted average shares outstanding: | |||||||||||||||||||||||
Basic | 702,382 | 547,026 | 651,642 | 546,936 | |||||||||||||||||||
Diluted | 703,268 | 547,294 | 652,113 | 547,204 |
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
Net income (loss) applicable to common shares | $ | 145,833 | $ | 51,750 | $ | 152,309 | $ | 169,449 | ||||||||||||||||||
Real estate related depreciation and amortization | 283,498 | 197,573 | 502,717 | 376,798 | ||||||||||||||||||||||
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures | 11,621 | 5,893 | 20,393 | 11,887 | ||||||||||||||||||||||
Noncontrolling interests’ share of real estate related depreciation and amortization | (4,732) | (4,685) | (9,174) | (9,470) | ||||||||||||||||||||||
Loss (gain) on sales of depreciable real estate, net | (122,044) | (4,885) | (125,299) | (86,463) | ||||||||||||||||||||||
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net | — | — | — | 11,546 | ||||||||||||||||||||||
Loss (gain) upon change of control, net(1) |
(198) | (234) | (77,978) | (234) | ||||||||||||||||||||||
Taxes associated with real estate dispositions(2) |
49 | — | 11,657 | — | ||||||||||||||||||||||
Nareit FFO applicable to common shares | 314,027 | 245,412 | 474,625 | 473,513 | ||||||||||||||||||||||
Distributions on dilutive convertible units and other | 4,583 | 2,342 | 5,281 | 4,687 | ||||||||||||||||||||||
Diluted Nareit FFO applicable to common shares | $ | 318,610 | $ | 247,754 | $ | 479,906 | $ | 478,200 | ||||||||||||||||||
Diluted Nareit FFO per common share | $ | 0.44 | $ | 0.45 | $ | 0.72 | $ | 0.86 | ||||||||||||||||||
Weighted average shares outstanding - Diluted Nareit FFO | 717,797 | 554,584 | 661,999 | 554,494 | ||||||||||||||||||||||
Impact of adjustments to Nareit FFO: | ||||||||||||||||||||||||||
Transaction and merger-related items(3) |
$ | 3,369 | $ | 581 | $ | 106,198 | $ | 2,944 | ||||||||||||||||||
Other impairments (recoveries) and other losses (gains), net(4) |
(553) | 2,432 | 11,300 | 1,159 | ||||||||||||||||||||||
Restructuring and severance-related charges | — | 1,368 | — | 1,368 | ||||||||||||||||||||||
Casualty-related charges (recoveries), net(5) |
(1,204) | (591) | (1,204) | (243) | ||||||||||||||||||||||
Total adjustments | 1,612 | 3,790 | 116,294 | 5,228 | ||||||||||||||||||||||
FFO as Adjusted applicable to common shares | 315,639 | 249,202 | 590,919 | 478,741 | ||||||||||||||||||||||
Distributions on dilutive convertible units and other | 4,581 | 2,338 | 6,960 | 4,680 | ||||||||||||||||||||||
Diluted FFO as Adjusted applicable to common shares | $ | 320,220 | $ | 251,540 | $ | 597,879 | $ | 483,421 | ||||||||||||||||||
Diluted FFO as Adjusted per common share | $ | 0.45 | $ | 0.45 | $ | 0.90 | $ | 0.87 | ||||||||||||||||||
Weighted average shares outstanding - Diluted FFO as Adjusted | 717,797 | 554,584 | 664,325 | 554,494 |
Three Months Ended June 30, |
Six Months Ended June 30, |
||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
FFO as Adjusted applicable to common shares | $ | 315,639 | $ | 249,202 | $ | 590,919 | $ | 478,741 | |||||||||||||||
Stock-based compensation amortization expense | 4,814 | 4,245 | 8,180 | 7,532 | |||||||||||||||||||
Amortization of deferred financing costs and debt discounts (premiums) | 7,317 | 2,954 | 11,840 | 5,774 | |||||||||||||||||||
Straight-line rents(1) |
(10,453) | (4,683) | (22,545) | (5,431) | |||||||||||||||||||
AFFO capital expenditures | (35,718) | (19,444) | (53,235) | (42,233) | |||||||||||||||||||
Deferred income taxes | 1,021 | (242) | 1,745 | (503) | |||||||||||||||||||
Amortization of above (below) market lease intangibles, net | (8,086) | (8,838) | (15,437) | (14,641) | |||||||||||||||||||
Other AFFO adjustments | (2,169) | (2,339) | (3,667) | (730) | |||||||||||||||||||
AFFO applicable to common shares | 272,365 | 220,855 | 517,800 | 428,509 | |||||||||||||||||||
Distributions on dilutive convertible units and other | 4,582 | 2,342 | 6,799 | 4,686 | |||||||||||||||||||
Diluted AFFO applicable to common shares | $ | 276,947 | $ | 223,197 | $ | 524,599 | $ | 433,195 | |||||||||||||||
Diluted AFFO per common share | $ | 0.39 | $ | 0.40 | $ | 0.79 | $ | 0.78 | |||||||||||||||
Weighted average shares outstanding - Diluted AFFO | 717,797 | 554,584 | 663,975 | 554,494 |
Definitions |
![]() |
2 |
Definitions |
![]() |
3 |
Definitions |
![]() |
4 |
Definitions |
![]() |
5 |
Definitions |
![]() |
6 |
Reconciliations | ||
Funds From Operations |
Three Months Ended June 30, |
Six Months Ended June 30, |
||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Net income (loss) applicable to common shares | $ | 145,833 | $ | 51,750 | $ | 152,309 | $ | 169,449 | |||||||||||||||
Real estate related depreciation and amortization | 283,498 | 197,573 | 502,717 | 376,798 | |||||||||||||||||||
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures | 11,621 | 5,893 | 20,393 | 11,887 | |||||||||||||||||||
Noncontrolling interests’ share of real estate related depreciation and amortization | (4,732) | (4,685) | (9,174) | (9,470) | |||||||||||||||||||
Loss (gain) on sales of depreciable real estate, net | (122,044) | (4,885) | (125,299) | (86,463) | |||||||||||||||||||
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net | — | — | — | 11,546 | |||||||||||||||||||
Loss (gain) upon change of control, net(1) |
(198) | (234) | (77,978) | (234) | |||||||||||||||||||
Taxes associated with real estate dispositions(2) |
49 | — | 11,657 | — | |||||||||||||||||||
Nareit FFO applicable to common shares | 314,027 | 245,412 | 474,625 | 473,513 | |||||||||||||||||||
Distributions on dilutive convertible units and other | 4,583 | 2,342 | 5,281 | 4,687 | |||||||||||||||||||
Diluted Nareit FFO applicable to common shares | $ | 318,610 | $ | 247,754 | $ | 479,906 | $ | 478,200 | |||||||||||||||
Weighted average shares outstanding - Diluted Nareit FFO | 717,797 | 554,584 | 661,999 | 554,494 | |||||||||||||||||||
Impact of adjustments to Nareit FFO: | |||||||||||||||||||||||
Transaction and merger-related items(3) |
$ | 3,369 | $ | 581 | $ | 106,198 | $ | 2,944 | |||||||||||||||
Other impairments (recoveries) and other losses (gains), net(4) |
(553) | 2,432 | 11,300 | 1,159 | |||||||||||||||||||
Restructuring and severance-related charges | — | 1,368 | — | 1,368 | |||||||||||||||||||
Casualty-related charges (recoveries), net(5) |
(1,204) | (591) | (1,204) | (243) | |||||||||||||||||||
Total adjustments | $ | 1,612 | $ | 3,790 | $ | 116,294 | $ | 5,228 | |||||||||||||||
FFO as Adjusted applicable to common shares | $ | 315,639 | $ | 249,202 | $ | 590,919 | $ | 478,741 | |||||||||||||||
Distributions on dilutive convertible units and other | 4,581 | 2,338 | 6,960 | 4,680 | |||||||||||||||||||
Diluted FFO as Adjusted applicable to common shares | $ | 320,220 | $ | 251,540 | $ | 597,879 | $ | 483,421 | |||||||||||||||
Weighted average shares outstanding - Diluted FFO as Adjusted | 717,797 | 554,584 | 664,325 | 554,494 | |||||||||||||||||||
FFO as Adjusted applicable to common shares | $ | 315,639 | $ | 249,202 | $ | 590,919 | $ | 478,741 | |||||||||||||||
Stock-based compensation amortization expense | 4,814 | 4,245 | 8,180 | 7,532 | |||||||||||||||||||
Amortization of deferred financing costs and debt discounts (premiums) | 7,317 | 2,954 | 11,840 | 5,774 | |||||||||||||||||||
Straight-line rents(6) |
(10,453) | (4,683) | (22,545) | (5,431) | |||||||||||||||||||
AFFO capital expenditures | (35,718) | (19,444) | (53,235) | (42,233) | |||||||||||||||||||
Deferred income taxes | 1,021 | (242) | 1,745 | (503) | |||||||||||||||||||
Amortization of above (below) market lease intangibles, net | (8,086) | (8,838) | (15,437) | (14,641) | |||||||||||||||||||
Other AFFO adjustments | (2,169) | (2,339) | (3,667) | (730) | |||||||||||||||||||
AFFO applicable to common shares | 272,365 | 220,855 | 517,800 | 428,509 | |||||||||||||||||||
Distributions on dilutive convertible units and other | 4,582 | 2,342 | 6,799 | 4,686 | |||||||||||||||||||
Diluted AFFO applicable to common shares | $ | 276,947 | $ | 223,197 | $ | 524,599 | $ | 433,195 | |||||||||||||||
Weighted average shares outstanding - Diluted AFFO | 717,797 | 554,584 | 663,975 | 554,494 |
![]() |
7 |
Reconciliations | ||
Funds From Operations |
Three Months Ended June 30, |
Six Months Ended June 30, |
||||||||||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Diluted earnings per common share | $ | 0.21 | $ | 0.09 | $ | 0.23 | $ | 0.31 | |||||||||||||||
Depreciation and amortization | 0.40 | 0.37 | 0.78 | 0.69 | |||||||||||||||||||
Loss (gain) on sales of depreciable real estate, net | (0.17) | (0.01) | (0.19) | (0.14) | |||||||||||||||||||
Loss (gain) upon change of control, net(1) |
0.00 | 0.00 | (0.12) | 0.00 | |||||||||||||||||||
Taxes associated with real estate dispositions(2) |
0.00 | — | 0.02 | — | |||||||||||||||||||
Diluted Nareit FFO per common share | $ | 0.44 | $ | 0.45 | $ | 0.72 | $ | 0.86 | |||||||||||||||
Transaction and merger-related items(3) |
0.01 | 0.00 | 0.16 | 0.01 | |||||||||||||||||||
Other impairments (recoveries) and other losses (gains), net(4) |
0.00 | 0.00 | 0.02 | 0.00 | |||||||||||||||||||
Restructuring and severance-related charges | — | 0.00 | 0.00 | 0.00 | |||||||||||||||||||
Casualty-related charges (recoveries), net(5) |
0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||||
Diluted FFO as Adjusted per common share | $ | 0.45 | $ | 0.45 | $ | 0.90 | $ | 0.87 | |||||||||||||||
Stock-based compensation amortization expense | 0.01 | 0.01 | 0.01 | 0.02 | |||||||||||||||||||
Amortization of deferred financing costs and debt discounts (premiums) | 0.01 | 0.01 | 0.02 | 0.01 | |||||||||||||||||||
Straight-line rents(6) |
(0.02) | (0.01) | (0.03) | (0.01) | |||||||||||||||||||
AFFO capital expenditures | (0.05) | (0.04) | (0.08) | (0.08) | |||||||||||||||||||
Deferred income taxes | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||||
Amortization of above (below) market lease intangibles, net | (0.01) | (0.02) | (0.02) | (0.03) | |||||||||||||||||||
Other AFFO adjustments | 0.00 | 0.00 | (0.01) | 0.00 | |||||||||||||||||||
Diluted AFFO per common share | $ | 0.39 | $ | 0.40 | $ | 0.79 | $ | 0.78 |
![]() |
8 |
Reconciliations | ||
2024 Guidance(1) |
2024 Guidance Ranges | |||||||||||
Low | High | ||||||||||
Diluted earnings per common share | $ | 0.27 | $ | 0.31 | |||||||
Real estate related depreciation and amortization | 1.57 | 1.57 | |||||||||
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures | 0.07 | 0.07 | |||||||||
Noncontrolling interests' share of real estate related depreciation and amortization | (0.03) | (0.03) | |||||||||
Loss (gain) on sales of depreciable real estate, net | (0.19) | (0.19) | |||||||||
Loss (gain) upon change of control, net | (0.12) | (0.12) | |||||||||
Taxes associated with real estate dispositions | 0.02 | 0.02 | |||||||||
Diluted Nareit FFO per common share | $ | 1.59 | $ | 1.63 | |||||||
Transaction and merger-related items | $ | 0.16 | $ | 0.16 | |||||||
Other impairments (recoveries) and other losses (gains), net | 0.02 | 0.02 | |||||||||
Diluted FFO as Adjusted per common share | $ | 1.77 | $ | 1.81 | |||||||
Stock-based compensation amortization expense | $ | 0.03 | $ | 0.03 | |||||||
Amortization of deferred financing costs and debt discounts (premiums) | 0.05 | 0.05 | |||||||||
Straight-line rents | (0.07) | (0.07) | |||||||||
AFFO capital expenditures | (0.18) | (0.18) | |||||||||
Amortization of above (below) market lease intangibles, net | (0.05) | (0.05) | |||||||||
Other AFFO adjustments | (0.01) | (0.01) | |||||||||
Diluted AFFO per common share | $ | 1.54 | $ | 1.58 |
![]() |
9 |
Reconciliations | ||
2024 Guidance(1) |
Total Portfolio | |||||
Net Income | $ | 213 | |||
Real estate related depreciation and amortization | 1,062 | ||||
Loss (gain) on sales of depreciable real estate, net | (125) | ||||
Other impairments (recoveries) and other losses (gains), net | 11 | ||||
Other income, costs, and expense adjustments for Cash (Adjusted) NOI | 315 | ||||
Cash (Adjusted) NOI | $ | 1,475 | |||
Pre-Merger legacy Physicians Realty Trust Adjusted NOI(2) |
60 | ||||
Merger-Combined non-SS Adjusted NOI | (181) | ||||
Total Merger-Combined Same-Store Cash (Adjusted) NOI | $ | 1,355 |
Total Portfolio | |||||
Net Income | $ | 233 | |||
Real estate related depreciation and amortization | 1,062 | ||||
Loss (gain) on sales of depreciable real estate, net | (125) | ||||
Other impairments (recoveries) and other losses (gains), net | 11 | ||||
Other income, costs, and expense adjustments for Cash (Adjusted) NOI | 315 | ||||
Cash (Adjusted) NOI | $ | 1,495 | |||
Pre-Merger legacy Physicians Realty Trust Adjusted NOI(2) |
60 | ||||
Merger-Combined non-SS Adjusted NOI | (181) | ||||
Total Merger-Combined Same-Store Cash (Adjusted) NOI | $ | 1,375 |
Total Portfolio | |||||
Net Income | $ | 335 | |||
Real estate related depreciation and amortization | 750 | ||||
Loss (gain) on sales of depreciable real estate, net | (86) | ||||
Other impairments (recoveries) and other losses (gains), net | (6) | ||||
Other income, costs, and expense adjustments for Cash (Adjusted) NOI | 212 | ||||
Cash (Adjusted) NOI | $ | 1,205 | |||
Pre-Merger legacy Physicians Realty Trust Adjusted NOI(2) |
360 | ||||
Merger-Combined non-SS Adjusted NOI | (247) | ||||
Total Merger-Combined Same-Store Cash (Adjusted) NOI | $ | 1,319 |
![]() |
10 |
Reconciliations | ||
2024 Guidance(1) |
Low | 2.75 | % | |||
High | 4.25 | % |
![]() |
11 |
Reconciliations | ||
Enterprise Gross Assets |
June 30, 2024 | |||||
Consolidated total assets(1) |
$ | 20,179,708 | |||
Investments in and advances to unconsolidated joint ventures | (927,204) | ||||
Accumulated depreciation and amortization of real estate | 3,796,108 | ||||
Accumulated amortization of real estate intangibles | 535,590 | ||||
Consolidated Gross Assets | $ | 23,584,202 | |||
Healthpeak's share of unconsolidated joint venture gross assets | 1,360,287 | ||||
Enterprise Gross Assets | $ | 24,944,489 | |||
Portfolio Investment |
June 30, 2024 | |||||||||||||||||||||||||||||
Outpatient Medical |
Lab | CCRC | Other | Total | |||||||||||||||||||||||||
Net real estate | $ | 7,598,132 | $ | 7,140,574 | $ | 1,659,168 | $ | — | $ | 16,397,874 | |||||||||||||||||||
Intangible assets, net | 910,250 | 64,346 | 101,491 | — | 1,076,087 | ||||||||||||||||||||||||
Accumulated depreciation and amortization of real estate | 1,881,311 | 1,517,366 | 397,431 | — | 3,796,108 | ||||||||||||||||||||||||
Accumulated amortization of real estate intangibles assets | 232,997 | 67,406 | 235,187 | — | 535,590 | ||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture gross real estate assets | 235,146 | 561,381 | — | 473,467 | 1,269,994 | ||||||||||||||||||||||||
Fully depreciated and amortized real estate and intangibles assets | 703,724 | 563,523 | 25,196 | — | 1,292,443 | ||||||||||||||||||||||||
Leasing commissions and other | 168,724 | 94,049 | — | — | 262,773 | ||||||||||||||||||||||||
Debt investments | — | — | — | 231,276 | 231,276 | ||||||||||||||||||||||||
Real estate intangible liabilities, gross | (256,566) | (190,922) | — | — | (447,488) | ||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture real estate and related intangibles | (416,780) | — | — | — | (416,780) | ||||||||||||||||||||||||
Portfolio Investment | $ | 11,056,938 | $ | 9,817,723 | $ | 2,418,473 | $ | 704,743 | $ | 23,997,877 |
![]() |
12 |
Reconciliations | ||
Revenues |
Three Months Ended | ||||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Outpatient Medical | $ | 186,661 | $ | 191,016 | $ | 188,835 | $ | 238,272 | $ | 332,515 | ||||||||||||||||||||||
Lab | 223,306 | 226,059 | 223,497 | 223,761 | 214,266 | |||||||||||||||||||||||||||
CCRC | 130,184 | 133,808 | 136,341 | 138,776 | 140,891 | |||||||||||||||||||||||||||
Other | 5,279 | 5,360 | 4,979 | 5,059 | 6,878 | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | 692 | 954 | |||||||||||||||||||||||||||
Total revenues | $ | 545,430 | $ | 556,243 | $ | 553,652 | $ | 606,560 | $ | 695,504 | ||||||||||||||||||||||
Outpatient Medical | — | — | — | — | — | |||||||||||||||||||||||||||
Lab | — | — | — | — | — | |||||||||||||||||||||||||||
CCRC | 47 | — | — | — | — | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Government grant income | $ | 47 | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||
Outpatient Medical | — | — | — | — | — | |||||||||||||||||||||||||||
Lab | — | — | — | — | — | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | (5,279) | (5,360) | (4,979) | (5,059) | (6,878) | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | (692) | (954) | |||||||||||||||||||||||||||
Less: Interest income and other | $ | (5,279) | $ | (5,360) | $ | (4,979) | $ | (5,751) | $ | (7,832) | ||||||||||||||||||||||
Outpatient Medical | 754 | 746 | 788 | 2,739 | 6,903 | |||||||||||||||||||||||||||
Lab | 1,928 | 2,425 | 3,406 | 4,861 | 4,301 | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | 20,261 | 20,572 | 21,247 | 21,533 | 21,378 | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture real estate revenues | $ | 22,943 | $ | 23,743 | $ | 25,441 | $ | 29,133 | $ | 32,582 | ||||||||||||||||||||||
Outpatient Medical | — | — | — | — | — | |||||||||||||||||||||||||||
Lab | — | — | — | — | — | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | — | — | 1 | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture government grant income | $ | — | $ | — | $ | 1 | $ | — | $ | — | ||||||||||||||||||||||
Outpatient Medical | (8,665) | (8,735) | (8,710) | (8,876) | (9,341) | |||||||||||||||||||||||||||
Lab | (151) | (154) | (171) | (163) | (33) | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture real estate revenues | $ | (8,816) | $ | (8,889) | $ | (8,881) | $ | (9,039) | $ | (9,374) | ||||||||||||||||||||||
![]() |
13 |
Reconciliations | ||
Revenues |
Three Months Ended | ||||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Outpatient Medical | $ | (4,685) | $ | (4,223) | $ | (3,612) | $ | (7,011) | $ | (12,101) | ||||||||||||||||||||||
Lab | (14,950) | (9,477) | (10,296) | (21,127) | (12,988) | |||||||||||||||||||||||||||
CCRC | — | — | (1) | 1 | (1) | |||||||||||||||||||||||||||
Other | 17 | (5) | (81) | (56) | (18) | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Non-cash adjustments to real estate revenues | $ | (19,618) | $ | (13,705) | $ | (13,990) | $ | (28,193) | $ | (25,108) | ||||||||||||||||||||||
Outpatient Medical | 174,064 | 178,804 | 177,301 | 225,124 | 317,976 | |||||||||||||||||||||||||||
Lab | 210,133 | 218,854 | 216,436 | 207,332 | 205,546 | |||||||||||||||||||||||||||
CCRC | 130,231 | 133,808 | 136,340 | 138,777 | 140,890 | |||||||||||||||||||||||||||
Other | 20,278 | 20,567 | 21,167 | 21,477 | 21,360 | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Portfolio Cash Real Estate Revenues(1) |
$ | 534,706 | $ | 552,033 | $ | 551,244 | $ | 592,710 | $ | 685,772 | ||||||||||||||||||||||
Outpatient Medical | 134,009 | 136,327 | 90,659 | 90,529 | — | |||||||||||||||||||||||||||
Lab | — | — | — | — | — | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Pre-Merger legacy Physicians Realty Trust Cash Real Estate Revenue | $ | 134,009 | $ | 136,327 | $ | 90,659 | $ | 90,529 | $ | — | ||||||||||||||||||||||
Outpatient Medical | (12,323) | (12,390) | 29,665 | (15,033) | (14,163) | |||||||||||||||||||||||||||
Lab | (43,404) | (48,594) | (48,259) | (37,671) | (33,384) | |||||||||||||||||||||||||||
CCRC | (231) | (205) | (257) | (299) | (306) | |||||||||||||||||||||||||||
Other | (20,278) | (20,567) | (21,167) | (21,477) | (21,360) | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Merger-Combined non-SS Cash Real Estate Revenues | $ | (76,236) | $ | (81,756) | $ | (40,018) | $ | (74,480) | $ | (69,213) | ||||||||||||||||||||||
Outpatient Medical | 295,750 | 302,741 | 297,625 | 300,620 | 303,813 | |||||||||||||||||||||||||||
Lab | 166,729 | 170,260 | 168,177 | 169,661 | 172,162 | |||||||||||||||||||||||||||
CCRC | 130,000 | 133,603 | 136,083 | 138,478 | 140,584 | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Merger-Combined SS Cash Real Estate Revenues(3) |
$ | 592,479 | $ | 606,604 | $ | 601,885 | $ | 608,759 | $ | 616,559 |
![]() |
14 |
Reconciliations | ||
Operating Expenses |
Three Months Ended | ||||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Outpatient Medical | $ | 65,350 | $ | 67,693 | $ | 65,691 | $ | 81,268 | $ | 111,702 | ||||||||||||||||||||||
Lab | 54,832 | 60,268 | 56,964 | 56,840 | 56,656 | |||||||||||||||||||||||||||
CCRC | 101,655 | 104,773 | 105,920 | 105,621 | 105,469 | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | (4,174) | — | — | |||||||||||||||||||||||||||
Operating expenses | $ | 221,837 | $ | 232,734 | $ | 224,401 | $ | 243,729 | $ | 273,827 | ||||||||||||||||||||||
Outpatient Medical | 288 | 301 | 295 | 1,083 | 2,464 | |||||||||||||||||||||||||||
Lab | 848 | 958 | 1,104 | 1,324 | 1,528 | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | 14,618 | 15,439 | 15,748 | 16,099 | 15,790 | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture operating expenses | $ | 15,754 | $ | 16,698 | $ | 17,147 | $ | 18,506 | $ | 19,782 | ||||||||||||||||||||||
Outpatient Medical | (2,409) | (2,474) | (2,443) | (2,430) | (2,609) | |||||||||||||||||||||||||||
Lab | (35) | (33) | (48) | (43) | (9) | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture operating expenses | $ | (2,444) | $ | (2,507) | $ | (2,491) | $ | (2,473) | $ | (2,618) | ||||||||||||||||||||||
Outpatient Medical | — | — | — | — | — | |||||||||||||||||||||||||||
Lab | — | — | — | — | — | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | (4,174) | — | — | |||||||||||||||||||||||||||
Non-property level operating expenses | $ | — | $ | — | $ | (4,174) | $ | — | $ | — | ||||||||||||||||||||||
Outpatient Medical | (677) | (676) | (675) | (884) | (1,671) | |||||||||||||||||||||||||||
Lab | (7) | 365 | 612 | 308 | 301 | |||||||||||||||||||||||||||
CCRC | 728 | — | 940 | 1 | 1,738 | |||||||||||||||||||||||||||
Other | 27 | 22 | (505) | (9) | (244) | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Non-cash adjustments to operating expenses | $ | 71 | $ | (289) | $ | 372 | $ | (584) | $ | 124 | ||||||||||||||||||||||
Outpatient Medical | 62,552 | 64,844 | 62,868 | 79,037 | 109,886 | |||||||||||||||||||||||||||
Lab | 55,638 | 61,558 | 58,632 | 58,429 | 58,476 | |||||||||||||||||||||||||||
CCRC | 102,383 | 104,773 | 106,860 | 105,622 | 107,207 | |||||||||||||||||||||||||||
Other | 14,645 | 15,461 | 15,243 | 16,090 | 15,546 | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Portfolio Cash Operating Expenses(2) |
$ | 235,218 | $ | 246,636 | $ | 243,603 | $ | 259,178 | $ | 291,115 |
![]() |
15 |
Reconciliations | ||
Operating Expenses |
Three Months Ended | ||||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Outpatient Medical | $ | 43,893 | $ | 46,243 | $ | 42,342 | $ | 29,131 | $ | — | ||||||||||||||||||||||
Lab | — | — | — | — | — | |||||||||||||||||||||||||||
CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Pre-Merger legacy Physicians Realty Trust Cash Operating Expenses | $ | 43,893 | $ | 46,243 | $ | 42,342 | $ | 29,131 | $ | — | ||||||||||||||||||||||
Outpatient Medical | (5,347) | (5,619) | (5,648) | (6,591) | (6,670) | |||||||||||||||||||||||||||
Lab | (8,218) | (9,846) | (10,595) | (9,381) | (9,193) | |||||||||||||||||||||||||||
CCRC | (445) | (537) | (504) | (627) | (440) | |||||||||||||||||||||||||||
Other | (14,645) | (15,461) | (15,243) | (16,090) | (15,546) | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Merger-Combined non-SS Cash Operating Expenses | $ | (28,655) | $ | (31,463) | $ | (31,990) | $ | (32,689) | $ | (31,849) | ||||||||||||||||||||||
Outpatient Medical | 101,098 | 105,468 | 99,562 | 101,577 | 103,216 | |||||||||||||||||||||||||||
Lab | 47,420 | 51,712 | 48,037 | 49,048 | 49,283 | |||||||||||||||||||||||||||
CCRC | 101,938 | 104,236 | 106,356 | 104,995 | 106,767 | |||||||||||||||||||||||||||
Other | — | — | — | — | — | |||||||||||||||||||||||||||
Corporate Non-segment | — | — | — | — | — | |||||||||||||||||||||||||||
Merger-Combined SS Cash Operating Expenses(3) |
$ | 250,456 | $ | 261,416 | $ | 253,955 | $ | 255,620 | $ | 259,266 |
![]() |
16 |
Reconciliations | ||
Revenue | Operating Expenses |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
||||||||||||||||
Outpatient Medical | $ | 570,787 | Outpatient Medical | $ | 192,970 | ||||||||||||
Lab | 438,027 | Lab | 113,496 | ||||||||||||||
CCRC | 279,667 | CCRC | 211,090 | ||||||||||||||
Other | 11,937 | Other | — | ||||||||||||||
Corporate Non-segment | 1,646 | Corporate Non-segment | — | ||||||||||||||
Total revenues | $ | 1,302,064 | Operating expenses | $ | 517,556 | ||||||||||||
Outpatient Medical | — | Outpatient Medical | 3,547 | ||||||||||||||
Lab | — | Lab | 2,852 | ||||||||||||||
CCRC | — | CCRC | — | ||||||||||||||
Other | (11,937) | Other | 31,889 | ||||||||||||||
Corporate Non-segment | (1,646) | Corporate Non-segment | — | ||||||||||||||
Less: Interest income and other | $ | (13,583) | Healthpeak's share of unconsolidated joint venture operating expenses | $ | 38,288 | ||||||||||||
Outpatient Medical | 9,642 | Outpatient Medical | (5,039) | ||||||||||||||
Lab | 9,162 | Lab | (52) | ||||||||||||||
CCRC | — | CCRC | — | ||||||||||||||
Other | 42,911 | Other | — | ||||||||||||||
Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
Healthpeak's share of unconsolidated joint venture real estate revenues | $ | 61,715 | Noncontrolling interests' share of consolidated joint venture operating expenses | $ | (5,091) | ||||||||||||
Outpatient Medical | (18,217) | Outpatient Medical | (2,555) | ||||||||||||||
Lab | (196) | Lab | 609 | ||||||||||||||
CCRC | — | CCRC | 1,739 | ||||||||||||||
Other | — | Other | (253) | ||||||||||||||
Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
Noncontrolling interests' share of consolidated joint venture real estate revenues | $ | (18,413) | Non-cash adjustments to operating expenses | $ | (460) | ||||||||||||
Outpatient Medical | (19,112) | Outpatient Medical | 188,923 | ||||||||||||||
Lab | (34,115) | Lab | 116,905 | ||||||||||||||
CCRC | — | CCRC | 212,829 | ||||||||||||||
Other | (74) | Other | 31,636 | ||||||||||||||
Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
Non-cash adjustments to real estate revenues | $ | (53,301) | Portfolio Cash Operating Expenses(2) |
$ | 550,293 | ||||||||||||
Outpatient Medical | 543,100 | Outpatient Medical | 29,131 | ||||||||||||||
Lab | 412,878 | Life science | — | ||||||||||||||
CCRC | 279,667 | CCRC | — | ||||||||||||||
Other | 42,837 | Other | — | ||||||||||||||
Corporate Non-segment | — | Corporate Non-Segment | — | ||||||||||||||
Portfolio Cash Real Estate Revenues(1) |
$ | 1,278,482 | Pre-Merger legacy Physicians Realty Trust Cash Operating Expenses | $ | 29,131 |
![]() |
17 |
Reconciliations | ||
Revenue | Operating Expenses |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
||||||||||||||||
Outpatient Medical | $ | 90,529 | Outpatient Medical | $ | (13,261) | ||||||||||||
Lab | — | Lab | (18,574) | ||||||||||||||
CCRC | — | CCRC | (1,067) | ||||||||||||||
Other | — | Other | (31,636) | ||||||||||||||
Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
Pre-Merger legacy Physicians Realty Trust Cash Real Estate Revenue | $ | 90,529 | Merger-Combined non-SS Cash Operating Expenses | $ | (64,538) | ||||||||||||
Outpatient Medical | (29,197) | Outpatient Medical | 204,793 | ||||||||||||||
Lab | (71,055) | Lab | 98,331 | ||||||||||||||
CCRC | (605) | CCRC | 211,762 | ||||||||||||||
Other | (42,837) | Other | — | ||||||||||||||
Corporate Non-segment | — | Corporate Non-segment | — | ||||||||||||||
Merger-Combined non-SS Cash Real Estate Revenues | $ | (143,694) | Merger-Combined SS Cash Operating Expenses(3) |
$ | 514,886 | ||||||||||||
Outpatient Medical | 604,432 | ||||||||||||||||
Lab | 341,823 | ||||||||||||||||
CCRC | 279,062 | ||||||||||||||||
Other | — | ||||||||||||||||
Corporate Non-segment | — | ||||||||||||||||
Merger-Combined SS Cash Real Estate Revenues(3) |
$ | 1,225,317 | |||||||||||||||
![]() |
18 |
Reconciliations | ||
Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS |
Total Portfolio | Three Months Ended | |||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Net income (loss) | $ | 56,199 | $ | 68,656 | $ | 75,395 | $ | 11,177 | $ | 152,716 | ||||||||||||||||||||||
Interest income and other | (5,279) | (5,360) | (4,979) | (5,751) | (7,832) | |||||||||||||||||||||||||||
Interest expense | 49,074 | 50,510 | 52,784 | 60,907 | 74,910 | |||||||||||||||||||||||||||
Depreciation and amortization | 197,573 | 184,559 | 188,544 | 219,219 | 283,498 | |||||||||||||||||||||||||||
General and administrative | 25,936 | 23,093 | 21,556 | 23,299 | 26,718 | |||||||||||||||||||||||||||
Transaction and merger-related costs | 637 | 36 | 14,417 | 107,220 | 7,759 | |||||||||||||||||||||||||||
Impairments and loan loss reserves, net | 2,607 | (550) | (5,445) | 11,458 | (553) | |||||||||||||||||||||||||||
(Gain) loss on sales of real estate, net | (4,885) | — | — | (3,255) | (122,044) | |||||||||||||||||||||||||||
Other (income) expense, net | (1,955) | (1,481) | (2,600) | (78,516) | (4,004) | |||||||||||||||||||||||||||
Government grant income | 47 | — | — | — | — | |||||||||||||||||||||||||||
Income tax (benefit) expense | 1,136 | 787 | (11,842) | 13,698 | 2,728 | |||||||||||||||||||||||||||
Equity (income) loss from unconsolidated joint ventures | (2,729) | (2,101) | (3,558) | (2,376) | (51) | |||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | 7,189 | 7,045 | 8,295 | 10,627 | 12,800 | |||||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | (6,372) | (6,382) | (6,390) | (6,566) | (6,756) | |||||||||||||||||||||||||||
Non-property level NOI | — | — | (4,174) | — | — | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(19,688) | (13,416) | (14,361) | (27,609) | (25,232) | |||||||||||||||||||||||||||
Portfolio Adjusted NOI | $ | 299,490 | $ | 305,396 | $ | 307,642 | $ | 333,532 | $ | 394,657 | ||||||||||||||||||||||
Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 90,116 | 90,084 | 48,317 | 61,398 | — | |||||||||||||||||||||||||||
Merger-Combined non-SS Adjusted NOI | (47,583) | (50,292) | (8,029) | (41,791) | (37,364) | |||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) |
$ | 342,023 | $ | 345,188 | $ | 347,930 | $ | 353,139 | $ | 357,293 |
Outpatient Medical |
Three Months Ended | |||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Net income (loss) | $ | 48,068 | $ | 48,906 | $ | 48,580 | $ | 49,684 | $ | 108,586 | ||||||||||||||||||||||
Interest expense | 1,924 | 1,947 | 1,979 | 3,131 | 4,070 | |||||||||||||||||||||||||||
Depreciation and amortization | 71,722 | 72,736 | 74,067 | 106,292 | 173,408 | |||||||||||||||||||||||||||
Transaction and merger-related costs | 16 | 23 | 949 | 113 | 41 | |||||||||||||||||||||||||||
(Gain) loss on sales of real estate, net | — | — | — | (3,255) | (66,831) | |||||||||||||||||||||||||||
Other (income) expense, net | (235) | (78) | (2,180) | (71) | (1,383) | |||||||||||||||||||||||||||
Equity (income) loss from unconsolidated joint ventures | (184) | (211) | (251) | 1,110 | 2,922 | |||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | 466 | 445 | 493 | 1,656 | 4,439 | |||||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | (6,256) | (6,261) | (6,267) | (6,446) | (6,732) | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(4,008) | (3,547) | (2,938) | (6,127) | (10,430) | |||||||||||||||||||||||||||
Portfolio Adjusted NOI | $ | 111,513 | $ | 113,960 | $ | 114,432 | $ | 146,087 | $ | 208,090 | ||||||||||||||||||||||
Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 90,116 | 90,084 | 48,317 | 61,398 | — | |||||||||||||||||||||||||||
Merger-Combined non-SS Adjusted NOI | (6,977) | (6,771) | 35,314 | (8,442) | (7,493) | |||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) |
$ | 194,652 | $ | 197,273 | $ | 198,063 | $ | 199,043 | $ | 200,597 |
![]() |
19 |
Reconciliations | ||
Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS |
Lab | Three Months Ended | |||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Net income (loss) | $ | 76,551 | $ | 88,337 | $ | 86,913 | $ | 169,798 | $ | 138,830 | ||||||||||||||||||||||
Depreciation and amortization | 93,235 | 78,646 | 80,886 | 78,908 | 75,947 | |||||||||||||||||||||||||||
Transaction and merger-related costs | — | 51 | 124 | 9 | 478 | |||||||||||||||||||||||||||
(Gain) loss on sales of real estate, net | — | — | — | — | (55,213) | |||||||||||||||||||||||||||
Other (income) expense, net | 2 | 1 | (6) | (78,983) | (185) | |||||||||||||||||||||||||||
Equity (income) loss from unconsolidated joint ventures | (1,314) | (1,244) | (1,384) | (2,811) | (2,247) | |||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | 1,080 | 1,467 | 2,302 | 3,537 | 2,773 | |||||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | (116) | (121) | (123) | (120) | (24) | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(14,943) | (9,842) | (10,907) | (21,435) | (13,289) | |||||||||||||||||||||||||||
Portfolio Adjusted NOI | $ | 154,495 | $ | 157,295 | $ | 157,805 | $ | 148,903 | $ | 147,070 | ||||||||||||||||||||||
Merger-Combined non-SS Adjusted NOI | (35,186) | (38,747) | (37,665) | (28,290) | (24,191) | |||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) |
$ | 119,309 | $ | 118,548 | $ | 120,140 | $ | 120,613 | $ | 122,879 |
CCRC | Three Months Ended | |||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Net income (loss) | $ | (5,514) | $ | (5,633) | $ | (6,213) | $ | (2,172) | $ | (160) | ||||||||||||||||||||||
Interest expense | 1,823 | 1,830 | 1,541 | 996 | 984 | |||||||||||||||||||||||||||
Depreciation and amortization | 32,616 | 33,177 | 33,591 | 34,019 | 34,143 | |||||||||||||||||||||||||||
Transaction and merger-related costs | 278 | (85) | 1,469 | 73 | (24) | |||||||||||||||||||||||||||
Other (income) expense, net | (674) | (254) | 33 | 239 | 479 | |||||||||||||||||||||||||||
Government grant income | 47 | — | — | — | — | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(728) | — | (940) | — | (1,739) | |||||||||||||||||||||||||||
Portfolio Adjusted NOI | $ | 27,848 | $ | 29,035 | $ | 29,481 | $ | 33,155 | $ | 33,683 | ||||||||||||||||||||||
Merger-Combined non-SS Adjusted NOI | 214 | 332 | 246 | 328 | 134 | |||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) |
$ | 28,062 | $ | 29,367 | $ | 29,727 | $ | 33,483 | $ | 33,817 |
Other | Three Months Ended | |||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Net income (loss) | $ | 8,769 | $ | 6,503 | $ | 12,338 | $ | (5,724) | $ | 8,195 | ||||||||||||||||||||||
Interest income and other | (5,279) | (5,360) | (4,979) | (5,059) | (6,878) | |||||||||||||||||||||||||||
Impairments and loan loss reserves, net | 2,607 | (550) | (5,445) | 11,458 | (553) | |||||||||||||||||||||||||||
(Gain) loss on sales of real estate, net | (4,885) | — | — | — | — | |||||||||||||||||||||||||||
Other (income) expense, net | 19 | 53 | 9 | — | (38) | |||||||||||||||||||||||||||
Equity (income) loss from unconsolidated joint ventures | (1,231) | (646) | (1,923) | (675) | (726) | |||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | 5,643 | 5,133 | 5,500 | 5,434 | 5,588 | |||||||||||||||||||||||||||
Adjustments to NOI(1) |
(9) | (27) | 424 | (47) | 226 | |||||||||||||||||||||||||||
Portfolio Adjusted NOI | $ | 5,634 | $ | 5,106 | $ | 5,924 | $ | 5,387 | $ | 5,814 | ||||||||||||||||||||||
Merger-Combined non-SS Adjusted NOI | (5,634) | (5,106) | (5,924) | (5,387) | (5,814) | |||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) |
$ | — | $ | — | $ | — | $ | — | $ | — |
![]() |
20 |
Reconciliations | ||
Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS |
Corporate Non-Segment |
Three Months Ended | |||||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||||||
Net income (loss) | $ | (71,675) | $ | (69,457) | $ | (66,223) | $ | (200,409) | $ | (102,735) | ||||||||||||||||||||||
Interest income and other | — | — | — | (692) | (954) | |||||||||||||||||||||||||||
Interest expense | 45,327 | 46,733 | 49,264 | 56,780 | 69,856 | |||||||||||||||||||||||||||
General and administrative | 25,936 | 23,093 | 21,556 | 23,299 | 26,718 | |||||||||||||||||||||||||||
Transaction and merger-related costs | 343 | 47 | 11,875 | 107,025 | 7,264 | |||||||||||||||||||||||||||
Other (income) expense, net | (1,067) | (1,203) | (456) | 299 | (2,877) | |||||||||||||||||||||||||||
Income tax (benefit) expense | 1,136 | 787 | (11,842) | 13,698 | 2,728 | |||||||||||||||||||||||||||
Non-property level NOI | — | — | (4,174) | — | — | |||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) |
$ | — | $ | — | $ | — | $ | — | $ | — |
![]() |
21 |
Reconciliations | ||
Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS |
Outpatient Medical |
Lab | CCRC | Other Non- reportable |
Corporate Non-segment |
Total | |||||||||||||||||||||||||||||||||
Net income (loss) | $ | 138,697 | $ | 308,630 | $ | (2,332) | $ | 2,470 | $ | (283,572) | $ | 163,893 | ||||||||||||||||||||||||||
Interest income and other | — | — | — | (11,937) | (1,646) | (13,583) | ||||||||||||||||||||||||||||||||
Interest expense | 26,775 | — | 1,979 | — | 107,063 | 135,817 | ||||||||||||||||||||||||||||||||
Depreciation and amortization | 279,699 | 154,855 | 68,163 | — | — | 502,717 | ||||||||||||||||||||||||||||||||
General and administrative | — | — | — | — | 50,017 | 50,017 | ||||||||||||||||||||||||||||||||
Transaction and merger-related costs | 154 | 486 | 49 | — | 114,290 | 114,979 | ||||||||||||||||||||||||||||||||
Impairments and loan loss reserves, net | — | — | — | 10,905 | — | 10,905 | ||||||||||||||||||||||||||||||||
(Gain) loss on sales of real estate, net | (70,086) | (55,213) | — | — | — | (125,299) | ||||||||||||||||||||||||||||||||
Other (income) expense, net | (1,454) | (79,168) | 718 | (38) | (2,578) | (82,520) | ||||||||||||||||||||||||||||||||
Income tax (benefit) expense | — | — | — | — | 16,426 | 16,426 | ||||||||||||||||||||||||||||||||
Equity (income) loss from unconsolidated joint ventures | 4,032 | (5,059) | — | (1,400) | — | (2,427) | ||||||||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | 6,095 | 6,310 | — | 11,022 | — | 23,427 | ||||||||||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | (13,178) | (144) | — | — | — | (13,322) | ||||||||||||||||||||||||||||||||
Adjustments to NOI(1) |
(16,556) | (34,724) | (1,739) | 179 | — | (52,840) | ||||||||||||||||||||||||||||||||
Portfolio Adjusted NOI | $ | 354,178 | $ | 295,973 | $ | 66,838 | $ | 11,201 | $ | — | $ | 728,190 | ||||||||||||||||||||||||||
Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 61,398 | — | — | — | — | 61,398 | ||||||||||||||||||||||||||||||||
Merger-Combined non-SS Adjusted NOI | (15,936) | (52,481) | 462 | (11,201) | — | (79,156) | ||||||||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) |
$ | 399,640 | $ | 243,492 | $ | 67,300 | $ | — | $ | — | $ | 710,432 |
![]() |
22 |
Reconciliations | ||
Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS |
Outpatient Medical |
Lab | CCRC | Other Non- reportable |
Corporate Non-segment |
Total | |||||||||||||||||||||||||||||||||
Net income (loss) | $ | 119,130 | $ | 209,809 | $ | (14,740) | $ | 17,942 | $ | (141,435) | $ | 190,706 | ||||||||||||||||||||||||||
Interest income and other | — | — | — | (11,442) | — | (11,442) | ||||||||||||||||||||||||||||||||
Interest expense | 3,845 | — | 3,639 | — | 89,553 | 97,037 | ||||||||||||||||||||||||||||||||
Depreciation and amortization | 142,881 | 168,817 | 65,100 | — | — | 376,798 | ||||||||||||||||||||||||||||||||
General and administrative | — | — | — | — | 50,483 | 50,483 | ||||||||||||||||||||||||||||||||
Transaction and merger-related costs | 148 | 158 | 497 | — | 2,259 | 3,062 | ||||||||||||||||||||||||||||||||
Impairments and loan loss reserves, net | — | — | — | 394 | — | 394 | ||||||||||||||||||||||||||||||||
(Gain) loss on sales of real estate, net | (21,312) | (60,498) | — | (4,653) | — | (86,463) | ||||||||||||||||||||||||||||||||
Other (income) expense, net | (439) | (2) | (7) | 19 | (2,298) | (2,727) | ||||||||||||||||||||||||||||||||
Government grant income | — | — | 184 | — | — | 184 | ||||||||||||||||||||||||||||||||
Income tax (benefit) expense | — | — | — | — | 1,438 | 1,438 | ||||||||||||||||||||||||||||||||
Equity (income) loss from unconsolidated joint ventures | (374) | (1,911) | — | (2,260) | — | (4,545) | ||||||||||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | 903 | 2,063 | — | 11,212 | — | 14,178 | ||||||||||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | (12,624) | (219) | — | — | — | (12,843) | ||||||||||||||||||||||||||||||||
Adjustments to NOI(1) |
(7,825) | (15,776) | (678) | (31) | — | (24,310) | ||||||||||||||||||||||||||||||||
Portfolio Adjusted NOI | $ | 224,333 | $ | 302,441 | $ | 53,995 | $ | 11,181 | $ | — | $ | 591,950 | ||||||||||||||||||||||||||
Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 179,632 | — | — | — | — | 179,632 | ||||||||||||||||||||||||||||||||
Merger-Combined non-SS Adjusted NOI | (14,985) | (65,707) | 523 | (11,181) | — | (91,350) | ||||||||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) |
$ | 388,980 | $ | 236,734 | $ | 54,518 | $ | — | $ | — | $ | 680,232 |
![]() |
23 |
Reconciliations | ||
Property Count Reconciliations |
As of June 30, 2024 | |||||||||||||||||||||||||||||
Property Count Reconciliation | |||||||||||||||||||||||||||||
Outpatient Medical |
Lab | CCRC | Other | Total | |||||||||||||||||||||||||
Prior Quarter Total Property Count | 594 | 146 | 15 | 19 | 774 | ||||||||||||||||||||||||
Assets sold | (11) | (7) | — | — | (18) | ||||||||||||||||||||||||
New Developments | 2 | — | — | — | 2 | ||||||||||||||||||||||||
Current Quarter Total Property Count | 585 | 139 | 15 | 19 | 758 | ||||||||||||||||||||||||
Recent acquisitions | (5) | — | — | — | (5) | ||||||||||||||||||||||||
Assets in Development | (6) | (4) | — | — | (10) | ||||||||||||||||||||||||
Recently completed Developments | (1) | (2) | — | — | (3) | ||||||||||||||||||||||||
Assets in Redevelopment | — | (15) | — | — | (15) | ||||||||||||||||||||||||
Recently completed Redevelopments | (4) | (4) | — | — | (8) | ||||||||||||||||||||||||
Segment exclusions | — | — | — | (19) | (19) | ||||||||||||||||||||||||
Significant tenant relocation | — | (2) | — | — | (2) | ||||||||||||||||||||||||
Three-Month SS Property Count | 569 | 112 | 15 | — | 696 | ||||||||||||||||||||||||
Six-Month SS Property Count | 569 | 112 | 15 | — | 696 |
Sequential SS | |||||||||||||||||||||||||||||
Outpatient Medical |
Lab | CCRC | Other | Total | |||||||||||||||||||||||||
Prior Quarter Three-Month SS Property Count | 580 | 119 | 15 | — | 714 | ||||||||||||||||||||||||
Assets sold | (11) | (7) | — | — | (18) | ||||||||||||||||||||||||
Current Quarter Three-Month SS Property Count | 569 | 112 | 15 | — | 696 |
![]() |
24 |
Reconciliations | ||
Common Stock and Equivalents |
Weighted Average Shares | Weighted Average Shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Outstanding June 30, 2024 |
Diluted EPS | Diluted Nareit FFO | Diluted FFO as Adjusted | Diluted AFFO | Diluted EPS | Diluted Nareit FFO | Diluted FFO as Adjusted | Diluted AFFO | |||||||||||||||||||||||||||||||||||||||||||||
Common stock | 700,317 | 702,382 | 702,382 | 702,382 | 702,382 | 651,642 | 651,642 | 651,642 | 651,642 | ||||||||||||||||||||||||||||||||||||||||||||
Common stock equivalent securities(1): |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock units | 968 | 135 | 135 | 135 | 135 | 157 | 157 | 157 | 157 | ||||||||||||||||||||||||||||||||||||||||||||
Dilutive impact of options | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
Equity forward agreements | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
OP units | 3,177 | 751 | 1,590 | 1,590 | 1,590 | 314 | 458 | 959 | 609 | ||||||||||||||||||||||||||||||||||||||||||||
Convertible partnership units | 13,669 | — | 13,690 | 13,690 | 13,690 | — | 9,742 | 11,567 | 11,567 | ||||||||||||||||||||||||||||||||||||||||||||
Total common stock and equivalents | 718,131 | 703,268 | 717,797 | 717,797 | 717,797 | 652,113 | 661,999 | 664,325 | 663,975 |
![]() |
25 |
Reconciliations | ||
Net Income to Adjusted EBITDAre |
Three Months Ended June 30, 2024 |
|||||
Net income (loss) | $ | 152,716 | |||
Interest expense | 74,910 | ||||
Income tax expense (benefit) | 2,728 | ||||
Depreciation and amortization | 283,498 | ||||
Other depreciation and amortization | 954 | ||||
Loss (gain) on sales of real estate | (122,044) | ||||
Loss (gain) upon change of control | (198) | ||||
Share of unconsolidated JV: | |||||
Interest expense | 3,493 | ||||
Income tax expense (benefit) | 180 | ||||
Depreciation and amortization | 11,621 | ||||
EBITDAre | $ | 407,858 | |||
Transaction and merger-related items | 3,369 | ||||
Other impairments (recoveries) and other losses (gains) | (553) | ||||
Casualty-related charges (recoveries) | (1,204) | ||||
Stock-based compensation amortization expense | 4,814 | ||||
Impact of transactions closed during the period(1) |
(3,239) | ||||
Adjusted EBITDAre | $ | 411,045 |
Adjusted Fixed Charge Coverage |
Three Months Ended June 30, 2024 |
|||||
Interest expense, including unconsolidated JV interest expense at share | $ | 78,403 | |||
Capitalized interest, including unconsolidated JV capitalized interest at share | 16,776 | ||||
Fixed Charges | $ | 95,179 | |||
Adjusted Fixed Charge Coverage | 4.3x |
![]() |
26 |
Reconciliations | ||
Enterprise Debt and Net Debt |
June 30, 2024 | |||||
Bank line of credit and commercial paper | $ | 25,000 | |||
Term loans | 1,645,456 | ||||
Senior unsecured notes | 6,551,155 | ||||
Mortgage debt | 381,416 | ||||
Consolidated Debt | $ | 8,603,027 | |||
Share of unconsolidated JV mortgage debt | 189,365 | ||||
Enterprise Debt | $ | 8,792,392 | |||
Cash and cash equivalents | (106,886) | ||||
Share of unconsolidated JV cash and cash equivalents | (28,472) | ||||
Restricted cash | (52,409) | ||||
Share of unconsolidated JV restricted cash | (6,509) | ||||
Net Debt | $ | 8,598,116 |
Financial Leverage |
June 30, 2024 | |||||
Enterprise Debt | $ | 8,792,392 | |||
Enterprise Gross Assets | 24,944,489 | ||||
Financial Leverage | 35.2% |
Secured Debt Ratio |
June 30, 2024 | |||||
Mortgage debt | $ | 381,416 | |||
Share of unconsolidated JV mortgage debt | 189,365 | ||||
Enterprise Secured Debt | $ | 570,781 | |||
Enterprise Gross Assets | $ | 24,944,489 | |||
Secured Debt Ratio | 2.3% |
Net Debt to Adjusted EBITDAre |
June 30, 2024 | |||||
Net Debt | $ | 8,598,116 | |||
Annualized Adjusted EBITDAre(1) |
1,644,180 | ||||
Net Debt to Adjusted EBITDAre | 5.2x |
![]() |
27 |
Reconciliations | ||
Healthpeak's Share of Unconsolidated Joint Venture NOI |
Total Portfolio | Three Months Ended | ||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
|||||||||||||||||||||||||
Equity income (loss) from unconsolidated joint ventures | $ | 2,729 | $ | 2,101 | $ | 3,558 | $ | 2,376 | $ | 51 | |||||||||||||||||||
Depreciation and amortization | 5,893 | 6,190 | 6,724 | 8,772 | 11,621 | ||||||||||||||||||||||||
General and administrative | 249 | 267 | 199 | 337 | 79 | ||||||||||||||||||||||||
Other (income) expense, net | (1,917) | (1,558) | (2,389) | (1,005) | 883 | ||||||||||||||||||||||||
Income tax (benefit) expense | 235 | 45 | 203 | 147 | 166 | ||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | $ | 7,189 | $ | 7,045 | $ | 8,295 | $ | 10,627 | $ | 12,800 |
Outpatient Medical | Three Months Ended | ||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
|||||||||||||||||||||||||
Equity income (loss) from unconsolidated joint ventures | $ | 184 | $ | 211 | $ | 251 | $ | (1,110) | $ | (2,922) | |||||||||||||||||||
Depreciation and amortization | 256 | 218 | 241 | 1,615 | 4,270 | ||||||||||||||||||||||||
General and administrative | 21 | 15 | (3) | 44 | 133 | ||||||||||||||||||||||||
Other (income) expense, net | — | — | — | 1,099 | 2,965 | ||||||||||||||||||||||||
Income tax (benefit) expense | 5 | 1 | 4 | 8 | (7) | ||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | $ | 466 | $ | 445 | $ | 493 | $ | 1,656 | $ | 4,439 |
Lab | Three Months Ended | ||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
|||||||||||||||||||||||||
Equity income (loss) from unconsolidated joint ventures | $ | 1,314 | $ | 1,244 | $ | 1,384 | $ | 2,811 | $ | 2,247 | |||||||||||||||||||
Depreciation and amortization | 1,415 | 1,568 | 1,992 | 2,573 | 2,693 | ||||||||||||||||||||||||
General and administrative | 209 | 220 | 134 | 217 | (53) | ||||||||||||||||||||||||
Other (income) expense, net | (1,858) | (1,565) | (1,208) | (2,064) | (2,114) | ||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | $ | 1,080 | $ | 1,467 | $ | 2,302 | $ | 3,537 | $ | 2,773 |
Other | Three Months Ended | ||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
|||||||||||||||||||||||||
Equity income (loss) from unconsolidated joint ventures | $ | 1,231 | $ | 646 | $ | 1,923 | $ | 675 | $ | 726 | |||||||||||||||||||
Depreciation and amortization | 4,222 | 4,404 | 4,491 | 4,584 | 4,658 | ||||||||||||||||||||||||
General and administrative | 19 | 32 | 68 | 76 | (1) | ||||||||||||||||||||||||
Other (income) expense, net | (59) | 7 | (1,181) | (40) | 32 | ||||||||||||||||||||||||
Income tax (benefit) expense | 230 | 44 | 199 | 139 | 173 | ||||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | $ | 5,643 | $ | 5,133 | $ | 5,500 | $ | 5,434 | $ | 5,588 |
![]() |
28 |
Reconciliations | ||
Healthpeak's Share of Unconsolidated Joint Venture NOI |
Outpatient Medical |
Lab | Other | Total | |||||||||||||||||||||||
Equity income (loss) from unconsolidated joint ventures | $ | (4,032) | $ | 5,058 | $ | 1,401 | $ | 2,427 | ||||||||||||||||||
Depreciation and amortization | 5,885 | 5,266 | 9,242 | 20,393 | ||||||||||||||||||||||
General and administrative | 177 | 164 | 75 | 416 | ||||||||||||||||||||||
Other (income) expense, net | 4,064 | (4,178) | (8) | (122) | ||||||||||||||||||||||
Income tax (benefit) expense | 1 | — | 312 | 313 | ||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | $ | 6,095 | $ | 6,310 | $ | 11,022 | $ | 23,427 |
Outpatient Medical |
Lab | Other | Total | |||||||||||||||||||||||
Equity income (loss) from unconsolidated joint ventures | $ | 374 | $ | 1,911 | $ | 2,260 | $ | 4,545 | ||||||||||||||||||
Depreciation and amortization | 494 | 2,936 | 8,457 | 11,887 | ||||||||||||||||||||||
General and administrative | 24 | 554 | 110 | 688 | ||||||||||||||||||||||
Other (income) expense, net | — | (3,338) | (55) | (3,393) | ||||||||||||||||||||||
Income tax (benefit) expense | 11 | — | 440 | 451 | ||||||||||||||||||||||
Healthpeak's share of unconsolidated joint venture NOI | $ | 903 | $ | 2,063 | $ | 11,212 | $ | 14,178 |
![]() |
29 |
Reconciliations | ||
Noncontrolling Interests' Share of Consolidated Joint Venture NOI |
Total Portfolio | Three Months Ended | ||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
|||||||||||||||||||||||||
Income (loss) from continuing operations attributable to noncontrolling interest | $ | 4,300 | $ | 4,442 | $ | 4,451 | $ | 4,501 | $ | 6,669 | |||||||||||||||||||
Depreciation and amortization | 4,593 | 4,474 | 4,502 | 4,452 | 4,614 | ||||||||||||||||||||||||
Other (income) expense, net | 40 | 6 | 23 | 124 | 84 | ||||||||||||||||||||||||
Dividends attributable to noncontrolling interest | (2,561) | (2,540) | (2,586) | (2,511) | (4,611) | ||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | $ | 6,372 | $ | 6,382 | $ | 6,390 | $ | 6,566 | $ | 6,756 |
Outpatient Medical | Three Months Ended | ||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
|||||||||||||||||||||||||
Income (loss) from continuing operations attributable to noncontrolling interest | $ | 3,032 | $ | 3,181 | $ | 3,162 | $ | 3,266 | $ | 5,398 | |||||||||||||||||||
Depreciation and amortization | 4,541 | 4,422 | 4,452 | 4,402 | 4,603 | ||||||||||||||||||||||||
Other (income) expense, net | 124 | 97 | 117 | 215 | 107 | ||||||||||||||||||||||||
Dividends attributable to noncontrolling interest | (1,441) | (1,439) | (1,464) | (1,437) | (3,376) | ||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | $ | 6,256 | $ | 6,261 | $ | 6,267 | $ | 6,446 | $ | 6,732 |
Lab | Three Months Ended | ||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
|||||||||||||||||||||||||
Income (loss) from continuing operations attributable to noncontrolling interest | $ | 1,078 | $ | 1,061 | $ | 1,093 | $ | 1,044 | $ | 949 | |||||||||||||||||||
Depreciation and amortization | 52 | 52 | 50 | 50 | 11 | ||||||||||||||||||||||||
Other (income) expense, net | (84) | (91) | (94) | (91) | (23) | ||||||||||||||||||||||||
Dividends attributable to noncontrolling interest | (930) | (901) | (926) | (883) | (913) | ||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | $ | 116 | $ | 121 | $ | 123 | $ | 120 | $ | 24 |
Corporate Non-segment | Three Months Ended | ||||||||||||||||||||||||||||
June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
|||||||||||||||||||||||||
Income (loss) from continuing operations attributable to noncontrolling interest | $ | 190 | $ | 200 | $ | 196 | $ | 191 | $ | 322 | |||||||||||||||||||
Dividends attributable to noncontrolling interest | (190) | (200) | (196) | (191) | (322) | ||||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | $ | — | $ | — | $ | — | $ | — | $ | — |
![]() |
30 |
Reconciliations | ||
Noncontrolling Interests' Share of Consolidated Joint Venture NOI |
Outpatient Medical |
Lab | Corporate Non-segment |
Total | |||||||||||||||||||||||
Income (loss) from continuing operations attributable to noncontrolling interest | $ | 8,664 | $ | 1,993 | $ | 513 | $ | 11,170 | ||||||||||||||||||
Depreciation and amortization | 9,005 | 61 | — | 9,066 | ||||||||||||||||||||||
Other (income) expense, net | 322 | (114) | — | 208 | ||||||||||||||||||||||
Dividends attributable to noncontrolling interest | (4,813) | (1,796) | (513) | (7,122) | ||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | $ | 13,178 | $ | 144 | $ | — | $ | 13,322 |
Outpatient Medical |
Lab | Corporate Non-segment |
Total | |||||||||||||||||||||||
Income (loss) from continuing operations attributable to noncontrolling interest | $ | 17,104 | $ | 2,561 | $ | 190 | $ | 19,855 | ||||||||||||||||||
(Gain) loss on sales of real estate, net | (11,133) | (413) | — | (11,546) | ||||||||||||||||||||||
Depreciation and amortization | 9,195 | 89 | — | 9,284 | ||||||||||||||||||||||
Other (income) expense, net | 340 | (187) | — | 153 | ||||||||||||||||||||||
Dividends attributable to noncontrolling interest | (2,882) | (1,831) | (190) | (4,903) | ||||||||||||||||||||||
Noncontrolling interests' share of consolidated joint venture NOI | $ | 12,624 | $ | 219 | $ | — | $ | 12,843 |
![]() |
31 |
Reconciliations | ||
REVPOR CCRC(1) |
Three Months Ended | |||||||||||||||||||||||||||||
REVPOR CCRC | June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||
Portfolio Cash Real Estate Revenues(2) |
$ | 130,231 | $ | 133,808 | $ | 136,340 | $ | 138,777 | $ | 140,980 | |||||||||||||||||||
Other adjustments to REVPOR CCRC(3) |
(184) | (206) | — | — | — | ||||||||||||||||||||||||
REVPOR CCRC revenues | $ | 130,046 | $ | 133,603 | $ | 136,340 | $ | 138,777 | $ | 140,890 | |||||||||||||||||||
Average occupied units/month | 5,925 | 5,956 | 6,031 | 6,043 | 6,049 | ||||||||||||||||||||||||
REVPOR CCRC per month(4) |
$ | 7,317 | $ | 7,477 | $ | 7,536 | $ | 7,655 | $ | 7,764 |
Three Months Ended | |||||||||||||||||||||||||||||
REVPOR CCRC excluding NREF Amortization | June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||
REVPOR CCRC revenues | $ | 130,046 | $ | 133,603 | $ | 136,340 | $ | 138,777 | $ | 140,890 | |||||||||||||||||||
NREF Amortization | (20,287) | (20,762) | (22,105) | (21,577) | (21,401) | ||||||||||||||||||||||||
REVPOR CCRC revenues excluding NREF Amortization | $ | 109,759 | $ | 112,841 | $ | 114,235 | $ | 117,200 | $ | 119,489 | |||||||||||||||||||
Average occupied units/month | 5,925 | 5,956 | 6,031 | 6,043 | 6,049 | ||||||||||||||||||||||||
REVPOR CCRC excluding NREF Amortization per month(4) |
$ | 6,175 | $ | 6,315 | $ | 6,314 | $ | 6,465 | $ | 6,585 |
![]() |
32 |
Reconciliations | ||
REVPOR(1) |
Three Months Ended | |||||||||||||||||||||||||||||
REVPOR Other | June 30, 2023 |
September 30, 2023 |
December 31, 2023 |
March 31, 2024 |
June 30, 2024 |
||||||||||||||||||||||||
Portfolio Cash Real Estate Revenues(2) |
$ | 20,278 | $ | 20,567 | $ | 21,167 | $ | 21,477 | $ | 21,360 | |||||||||||||||||||
Other adjustments to REVPOR(3) |
(2,365) | (2,456) | — | — | — | ||||||||||||||||||||||||
REVPOR revenues | $ | 17,914 | $ | 18,111 | $ | 21,167 | $ | 21,477 | $ | 21,360 | |||||||||||||||||||
Average occupied units/month | 1,303 | 1,320 | 1,410 | 1,401 | 1,415 | ||||||||||||||||||||||||
REVPOR per month(4) |
$ | 4,584 | $ | 4,573 | $ | 5,005 | $ | 5,109 | $ | 5,032 |
![]() |
33 |
![]() |
34 |